Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COR-001 in Chronic Kidney Disease
NCT03126318Phase 1Completed
- Sponsor
- University of Colorado Denver
- Start
- May 2017
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic kidney disease (CKD) comparing COR-001 with Placebo (2 arms). Primary endpoint: Incidence of adverse events at 1 month. Started May 2017; status: completed.
02
Drugs
ziltivekimab
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT03126318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03126318.